Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Form 6-K overview
Dr. Reddy’s Laboratories Limited (RDY) filed a Form 6-K with the SEC dated 23 June 2025. The submission contains one exhibit—Exhibit 99.1: “Intimation regarding Board Meeting.” No financial statements, earnings figures, or major transactional details accompany the notice. The company confirms it files annual reports on Form 20-F and is not claiming the Rule 12g3-2(b) exemption. The filing is signed by Company Secretary K Randhir Singh from the Hyderabad headquarters.
Because the document simply alerts investors that a board meeting will be convened, without disclosing the meeting date, agenda, or potential resolutions, it offers no material information likely to impact valuation or strategy.
Dr. Reddy’s Laboratories Limited (NYSE: RDY) filed a routine Form 6-K with the U.S. SEC dated 20 June 2025. The submission contains only the cover page, signature page and an index showing a single exhibit—Exhibit 99.1: “Intimation dated June 20, 2025.” The actual exhibit text and any related financial, operational or strategic information are not included in the material provided for review. Therefore, no financial results, guidance updates, transactions, regulatory actions or other material events can be assessed from this filing alone.
The filing confirms that RDY continues to report under Form 20-F for annual statements and that this 6-K is being furnished—not filed—for SEC purposes, preserving safe-harbor protections. The document was signed by Company Secretary K Randhir Singh.
Because the substantive Exhibit 99.1 content is unavailable, the investor impact of this 6-K cannot be determined based on the information supplied.
On June 20, 2025, Dr. Reddy’s Laboratories Limited (NYSE: RDY) furnished a routine Form 6-K to the U.S. Securities and Exchange Commission. The filing affirms that the company continues to submit its annual reports on Form 20-F and is not relying on the Rule 12g3-2(b) exemption. The sole attachment is Exhibit 99.1 – “Intimation dated June 20, 2025.” The document was signed by Company Secretary K Randhir Singh. No financial statements, earnings figures, or descriptions of material transactions accompany this report, indicating that the submission is administrative in nature and unlikely to affect the company’s financial outlook or valuation.